Details of the Drug Combinations

General Information of This Drug (ID: DMZMSPF)

• Drug Name: Bicalutamide (DMZMSPF)
• Synonyms: Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide

Indication

Prostate cancer; ICD 11: 2C82.0; Status: Approved [1]; Castration-resistant prostate carcinoma; ICD 11: N.A.; Status: Investigative [2]; Metastatic prostate carcinoma; ICD 11: N.A.; Status: Investigative [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bicalutamide + Idarubicin	DCUT5EA	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]

17 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Anastrozole + Bicalutamide	DCJJT6T	Anastrozole	Puberty, Precocious	[4]
Camostat + Bicalutamide	DCTSLK5	Camostat	Covid19	[5]
Dutasteride + Bicalutamide	DCN1TLS	Dutasteride	Neoplasms, Prostate	[6]
Eflornithine + Bicalutamide	DCONSG6	Eflornithine	Prostate Cancer	[7]
Enzastaurin + Bicalutamide	DC9OFZ0	Enzastaurin	Prostate Cancer	[8]
Everolimus + Bicalutamide	DCOJ1TH	Everolimus	Prostate Cancer	[9]
Goserelin + Bicalutamide	DC1URFF	Goserelin	Prostate Cancer	[10]
Leuprolide + Bicalutamide	DCWYSTW	Leuprolide	Prostatic Neoplasms	[11]
Leuprolide + Bicalutamide	DC6UM7H	Leuprolide	Adenocarcinoma of the Prostate	[12]
LY2835219 + Bicalutamide	DC9WWHD	LY2835219	Breast Cancer	[13]
Panobinostat + Bicalutamide	DCGOER4	Panobinostat	Prostate Cancer	[14]
Raloxifene + Bicalutamide	DCCG9N8	Raloxifene	Prostate Cancer	[15]
Temsirolimus + Bicalutamide	DCT658G	Temsirolimus	Prostate Cancer	[16]
Vandetanib + Bicalutamide	DC5N9RD	Vandetanib	Prostate Cancer	[17]
Gonadorelin + Bicalutamide	DCBGLV0	Gonadorelin	Prostate Cancer	[18]
Letrozole + Bicalutamide	DCAZI7U	Letrozole	Breast Cancer	[19]
Raloxifene + Bicalutamide	DC62EEG	Raloxifene	Stage I Prostate Adenocarcinoma	[20]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2863).
• [2] Bicalutamide FDA Label
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT00094328) Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
• [5] ClinicalTrials.gov (NCT04652765) Camostat With Bicalutamide for COVID-19
• [6] ClinicalTrials.gov (NCT00470834) Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
• [7] ClinicalTrials.gov (NCT00086736) Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
• [8] ClinicalTrials.gov (NCT00685633) Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
• [9] ClinicalTrials.gov (NCT00630344) RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
• [10] ClinicalTrials.gov (NCT00002651) SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
• [11] ClinicalTrials.gov (NCT00514917) A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
• [12] ClinicalTrials.gov (NCT02064036) Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
• [13] ClinicalTrials.gov (NCT05095207) Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
• [14] ClinicalTrials.gov (NCT00878436) Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
• [15] ClinicalTrials.gov (NCT01050842) Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
• [16] ClinicalTrials.gov (NCT01020305) Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
• [17] ClinicalTrials.gov (NCT00659438) Efficacy and Safety of Zactima?in Patients With Castration-refractory Metastatic Prostate Cancer
• [18] ClinicalTrials.gov (NCT03141671) Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
• [19] ClinicalTrials.gov (NCT02910050) Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
• [20] ClinicalTrials.gov (NCT03147196) Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery